Xiaohui Du, PhD

Xiaohui brings more than 19 years of industry experience in drug discovery to Septerna. In her current role, Xiaohui is leading multiple research programs and is in charge of external chemistry operations and IP strategy.

Prior to Septerna, Xiaohui was Head of Medicinal Chemistry for Carmot Therapeutics. She led the team that discovered CT-996, a small molecule GLP-1R agonist for the treatment of type 2 diabetes and obesity, which was a key part of Carmot’s $2.7 billion acquisition by Roche. Previously, Xiaohui was a founding team member of ORIC Pharmaceuticals and made a number of key contributions to its oncology portfolio, including the discovery of ORIC-533. Prior to ORIC, Xiaohui spent a decade at Amgen in roles spanning metabolic, cardiovascular, inflammation, and oncology indications.

Xiaohui received her PhD in organic chemistry from University of California, Los Angeles, and was a NIH postdoctoral fellow at University of California, San Francisco. Xiaohui has authored more than 50 publications, including more than 20 papers and more than 30 patents.